Photofrin, Photobarr(porfimer sodium)
PhotoBarr, Photofrin (porfimer sodium) is a small molecule pharmaceutical. Porfimer sodium was first approved as Photofrin on 1995-12-27. It has been approved in Europe to treat barrett esophagus.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
Photofrin
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Porfimer sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PHOTOFRIN | Pinnacle Biologics | N-020451 RX | 1995-12-27 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| photofrin | New Drug Application | 2023-08-15 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9600 | Injection, porfimer sodium, 75 mg |
Clinical
Clinical Trials
51 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cholangiocarcinoma | D018281 | — | C22.1 | — | 3 | 7 | — | 3 | 11 |
| Recurrence | D012008 | — | — | 2 | 2 | 1 | — | — | 5 |
| Carcinoma | D002277 | — | C80.0 | 2 | 2 | 1 | — | 1 | 5 |
| Barrett esophagus | D001471 | EFO_0000280 | K22.7 | — | 3 | 2 | — | 1 | 5 |
| Esophageal neoplasms | D004938 | — | C15 | — | 2 | 1 | — | 1 | 4 |
| Bile duct neoplasms | D001650 | — | — | — | 2 | 3 | — | — | 4 |
| Central nervous system neoplasms | D016543 | — | — | 1 | — | 2 | — | — | 3 |
| Nervous system neoplasms | D009423 | — | — | 1 | — | 2 | — | — | 3 |
| Gallbladder neoplasms | D005706 | EFO_0004606 | C23 | — | 1 | 2 | — | — | 3 |
| Pathologic constriction | D003251 | — | — | — | 1 | 1 | — | 1 | 2 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 6 | 3 | — | — | 6 | 14 |
| Non-small-cell lung carcinoma | D002289 | — | — | 5 | 3 | — | — | 2 | 9 |
| Malignant mesothelioma | D000086002 | — | — | 1 | 3 | — | — | 1 | 5 |
| Mesothelioma | D008654 | — | C45 | 1 | 3 | — | — | 1 | 5 |
| Head and neck neoplasms | D006258 | — | — | 1 | 2 | — | — | 1 | 4 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | 1 | 3 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 2 | 1 | — | — | — | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 2 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | — | — | 1 | 2 |
| Small cell lung carcinoma | D055752 | — | — | 1 | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pleural diseases | D010995 | — | — | 2 | — | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | 1 | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
| Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
| Acinar cell carcinoma | D018267 | — | — | 1 | — | — | — | — | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ureteral obstruction | D014517 | HP_0006000 | — | — | — | — | — | 1 | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | — | — | 1 | 1 |
| Obstructive jaundice | D041781 | EFO_1001068 | — | — | — | — | — | 1 | 1 |
| Jaundice | D007565 | HP_0000952 | R17 | — | — | — | — | 1 | 1 |
| Disease progression | D018450 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Porfimer sodium |
| INN | porfimer sodium |
| Description | Porfimer sodium, sold as Photofrin, is a photosensitizer used in photodynamic therapy and radiation therapy and for palliative treatment of obstructing endobronchial non-small cell lung carcinoma and obstructing esophageal cancer.
|
| Classification | Small molecule |
| Drug class | polymers |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 87806-31-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201481 |
| ChEBI ID | 60652 |
| PubChem CID | 57166 |
| DrugBank | DB00707 |
| UNII ID | M15H03K69B (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,986 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
358 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use